Stop TB Partnership’s Global Drug Facility (GDF) undertakes monthly missions to provide technical assistance to countries and support to National TB Programs in managing procurement
Read below about the latest missions and updates
June, 2018 - The Global Drug Facility (GDF) of the Stop TB Partnership, participated in numerous Missions and meetings in the month of June 2018. From 28 May -1 June 2018 GDF was present in Morogoro, Tanzania at a National TB Medicines Quantification Review Workshop. The focus of the 5-day workshop was to provide technical assistance to the National TB Program Tanzania in the review of TB commodities quantification and the supply plan for 2018/2019. The meeting was organized by the Ministry of Health, Community Development, Gender, elderly and Children (MOHCDGEC)/NTP with funding from the Global Fund.
From 18-20 June, GDF took part in the WHO/EURO and Regional Green Light Committee for Europe (rGLC/Europe) as well as a Workshop titled “Programmatic aspects of the implementation of new TB drugs and regimens” in Copenhagen, Denmark. The objectives included discussing the uptake of new WHO policies on MDR-TB care through the lens of early experience in implementing countries, including experience of the endTB project in European countries. To assist countries in the process of revising their national policies based on current WHO policies and current programmatic experience and to update and align regional policies, treatment strategies, regimens and drugs used for the treatment composition with WHO’s global recommendations.
GDF also made it to Papua New Guinea (PNG) which has the highest TB incidence rate in the Western Pacific Region for a Technical Assistance Mission. From 2007 until now, The Stop TB Partnership’s GDF has provided procurement assistance to PNG in the provision of quality-assured first line and second line anti-TB medicines, as well as diagnostic consumables. Demand for TB treatments has steadily increased over the years, as the program is expanding access and implementation of new tools such as new pediatric formulations and rapid diagnostic tests. The key objectives of the Mission included reviewing and updating the quantification, supply planning, order management, and early warning system in TB medicines and diagnostics and providing technical assistance to revise and improve existing patient and stock related data among others.